Enlivex Therapeutics
Open
$0.68
Prev. Close
$0.68
High
$0.68
Low
$0.68
Market Snapshot
$16.28M
0.0
-0.73
34
Enlivex Ltd. engages in the development of macrophage reprogramming immunotherapy products. The company is headquartered in Ness Ziona, Central(Hamerkaz) and currently employs 34 full-time employees. The company went IPO on 2014-07-30. The firm focuses on diseases in which macrophages are pathologically reprogrammed, such as solid cancers, sepsis and COVID‑19, where non-homeostatic macrophages contribute significantly to disease severity. By re-establishing macrophage homeostasis, Allocetra has the potential to provide an immunotherapeutic mechanism of action for life-threatening indications defined as unmet medical needs, either as a stand‑alone therapy or in combination with other treatments.
Enlivex Ltd. engages in the development of macrophage reprogramming immunotherapy products. The company is headquartered in Ness Ziona, Central(Hamerkaz) and currently employs 34 full-time employees. The company went IPO on 2014-07-30. The firm focuses on diseases in which macrophages are pathologically reprogrammed, such as solid cancers, sepsis and COVID‑19, where non-homeostatic macrophages contribute significantly to disease severity. By re-establishing macrophage homeostasis, Allocetra has the potential to provide an immunotherapeutic mechanism of action for life-threatening indications defined as unmet medical needs, either as a stand‑alone therapy or in combination with other treatments.
Recently from Cashu
Enlivex Advances Allocetra, Promising New Therapy for Severe Sepsis and Immune Modulation
Enlivex Therapeutics Advances in Cell Therapy with Promising Clinical Results In a significant advancement for Enlivex Therapeutics, the company showcases promising outcomes from its leading investiga…
Enlivex Therapeutics Progresses Allocetra™ Cell Therapy in Immuno-Oncology Clinical Trials
Enlivex Therapeutics Advances Cell Therapy in Immuno-Oncology Enlivex Therapeutics, a company specializing in the field of immunology, focuses its efforts on developing innovative cell therapies that…
Enlivex Therapeutics: Breakthrough Clinical Results for Immunotherapy Product Allocetra in Critical Care
Enlivex Therapeutics Advances in Immunotherapy with Groundbreaking Clinical Trial Results Enlivex Therapeutics, a clinical-stage immunotherapy company, announces significant advancements in its clinic…
Enlivex Therapeutics Advances Allocetra™ Immunotherapy for Revolutionary Sepsis Treatment Solutions
### Enlivex Therapeutics Advances in Immunotherapy for Sepsis Treatment Enlivex Therapeutics is making significant strides in the field of immunotherapy, specifically targeting the treatment of sepsis…